Send to

Choose Destination
Toxicol Appl Pharmacol. 2019 Apr 26;374:32-40. doi: 10.1016/j.taap.2019.04.019. [Epub ahead of print]

Preclinical evaluation of the maximum tolerated dose and toxicokinetics of enteric-coated lantibiotic OG253 capsules.

Author information

Intrexon Corporation, Human Therapeutics Division, 20358 Seneca Meadows Pkwy, Germantown, MD 20876, USA.
Intrexon Corporation, Industrial Products Division, 29 Oyster Point Blvd., South San Francisco, CA 94080, USA.
Oragenics, Inc., 13700 Progress Blvd., Alachua, FL 32608, USA.
Oragenics, Inc., 13700 Progress Blvd., Alachua, FL 32608, USA. Electronic address:


Clostridium difficile associated disease (CDAD) is the leading infectious cause of antibiotic-associated diarrhea and colitis in the United States. Both the incidence and severity of CDAD have been increased over the past two decades. We evaluated the maximum tolerated dose (MTD) and toxicokinetics of OG253, a novel lantibiotic in development for the treatment of CDAD. OG253 was orally administered to Wistar Han rats as enteric-coated capsules in a one-day dose escalation study, followed by a seven-day repeated dose toxicokinetics study. All three doses of OG253 (6.75, 27 and 108 mg/day) were generally well-tolerated with no treatment-related clinical signs, alterations in body weight or food consumption in both one-day acute tolerability and seven-days repeated dose tolerability and toxicokinetics study. OG253 capsule administration neither significantly alter the weight of organs nor affect the hematology, coagulation, clinical biochemistry parameters and urine pH compared to placebo capsule administered rats. LC-MS/MS analysis did not detect OG253 in the plasma, indicating that OG253 is not absorbed into the blood from the rat gastrointestinal tract. Glandular atrophy of the rectal mucosa was noticed in two out of six rats administered with a high dose of OG253. Surprisingly, we found that OG253 treatment significantly lowered both serum cholesterol and triglyceride levels in both sexes of rats. Overall, there was a 29.8 and 61.38% decrease in the serum cholesterol and triglyceride levels, respectively as compared to placebo-treated rats. The well-tolerated high dose of OG253 (425.7 mg/kg/day) is recommended as the MTD for safety and efficacy studies. Further preclinical study is needed to evaluate the safety profile of OG253 under longer exposure.


Bacteriocin; CDAD; Lanthipeptide; Lantibiotic; Mutacin; Nisin and Toxicokinetics; OG253


Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center